|Articles|July 17, 2023

Identifying COVID-19 Risk Factors: Insights From 4 Vaccine Trials

Author(s)Nina Cosdon

Workplace exposure and living conditions were associated with higher COVID-19 risk, while previous infection, age 65 or older, and Black/African American race were correlated with lower COVID-19 rates.

As the COVID-19 pandemic continues to impact communities worldwide, understanding the risk factors associated with infection and severe outcomes is of utmost importance.

Existing data on COVID-19 risk factors often lack standardized outcomes and may not adequately control for confounding variables. In an effort to address these limitations, a recent secondary cross-protocol analysis was conducted and published in JAMA.

The studydraws on data from 4 multicenter, international, randomized, blinded, placebo-controlled COVID-19 vaccine efficacy trials. The study aimed to identify risk factors associated with COVID-19, severe COVID-19, and SARS-CoV-2 infection, providing valuable insights for future mitigation strategies.

Exposure and Demographic Factors Play Pivotal Roles

The analysis encompassed a diverse cohort of 57,692 participants, with a median age of 51 years, including a significant representation of individuals aged 65 and older (20.3%) and assigned male at birth (53.8%). The study population comprised various racial and ethnic backgrounds, including American Indian or Alaska Native (5.7%), Black or African American (13.6%), Hispanic or Latino (30.6%), and White (70.6%) participants.

Notably, exposure and demographic factors emerged as primary determinants of COVID-19 outcomes. Factors associated with an increased risk of COVID-19 included workplace exposure and living conditions. Conversely, previous SARS-CoV-2 infection, age 65 or older, and Black or African American race were associated with decreased rates of COVID-19.

Identifying Severe COVID-19 Risk Factors

The study also delved into severe COVID-19 risk factors among individuals who contracted COVID-19. Age of 65 years or older, American Indian/Alaska Native, Black/African American race, higher body mass index, and diabetes were linked to increased rates of severe COVID-19. However, previous SARS-CoV-2 infection was associated with a notably decreased risk of severe outcomes.

Implications for Mitigation Strategies

These findings hold significant implications for shaping effective mitigation strategies against COVID-19 and other viruses with similar epidemiological characteristics. By identifying the factors that influence COVID-19 susceptibility and severity, public health authorities can target interventions more precisely and prioritize vulnerable populations.

Workplace safety measures and improved living conditions could potentially reduce COVID-19 transmission rates, while vaccination efforts should be tailored to protect high-risk groups, such as older adults and specific racial or ethnic backgrounds.

The comprehensive analysis of COVID-19 risk factors from four randomized clinical trials offers valuable insights into the complex interplay between exposure, demographics, and disease outcomes. Understanding these factors is essential for designing targeted strategies to combat the ongoing pandemic and inform future responses to similar viral threats. As the global health community continues its fight against COVID-19, this study provides critical knowledge to safeguard the health of populations worldwide.


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
FAQ: Ebola Prevention, Treatment and the Chances of a US Outbreak
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.